2.1 Data Source
This study was designed as a retrospective study, the interventions of interest was voriconazole. All records in the FAERS database from January 2004 to March 2022 were included in this study [8]. We used both generic names and brand names to identify voriconazole and control drugs (see details in Supplementary Materials Table S1 ).
A deduplication procedure was performed according to the FDA’s recommendations to select the latest FDA_DT with the same CASEID and select the higher PRIMARYID when CASEID and FDA_DT are both the same adverse events (AE) were included when they were considered the “Primary Suspect (PS) drug (drugs which directly suspected of causing the adverse events)”.